



Year: 2014

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Stupp, R; Hegi, M E; Gorlia, T; et al; Kim, C Y; Nabors, L B; Reardon, D A; van den Bent, M J; Hicking, C; Markivskyy, A; Picard, M; Weller, M

Abstract: **BACKGROUND** Cilengitide is a selective α_3 and α_5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter). We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter. **METHODS** In this multicentre, open-label, phase 3 study, we investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries. Eligible patients (newly diagnosed, histologically proven supratentorial glioblastoma, methylated MGMT promoter, and age ≥ 18 years) were stratified for prognostic Radiation Therapy Oncology Group recursive partitioning analysis class and geographic region and centrally randomised in a 1:1 ratio with interactive voice response system to receive temozolomide chemoradiotherapy with cilengitide 2000 mg intravenously twice weekly (cilengitide group) or temozolomide chemoradiotherapy alone (control group). Patients and investigators were unmasked to treatment allocation. Maintenance temozolomide was given for up to six cycles, and cilengitide was given for up to 18 months or until disease progression or unacceptable toxic effects. The primary endpoint was overall survival. We analysed survival outcomes by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00689221. **FINDINGS** Overall, 3471 patients were screened. Of these patients, 3060 had tumour MGMT status tested; 926 patients had a methylated MGMT promoter, and 545 were randomly assigned to the cilengitide ($n=272$) or control groups ($n=273$) between Oct 31, 2008, and May 12, 2011. Median overall survival was 26.3 months (95% CI 23.8-28.8) in the cilengitide group and 26.3 months (23.9-34.7) in the control group (hazard ratio 1.02, 95% CI 0.81-1.29, $p=0.86$). None of the predefined clinical subgroups showed a benefit from cilengitide. We noted no overall additional toxic effects with cilengitide treatment. The most commonly reported adverse events of grade 3 or worse in the safety population were lymphopenia (31 [12%] in the cilengitide group vs 26 [10%] in the control group), thrombocytopenia (28 [11%] vs 46 [18%]), neutropenia (19 [7%] vs 24 [9%]), leucopenia (18 [7%] vs 20 [8%]), and convulsion (14 [5%] vs 15 [6%]). **INTERPRETATION** The addition of cilengitide to temozolomide chemoradiotherapy did not improve outcomes; cilengitide will not be further developed as an anticancer drug. Nevertheless, integrins remain a potential treatment target for glioblastoma. **FUNDING** Merck KGaA, Darmstadt, Germany.

DOI: [https://doi.org/10.1016/S1470-2045\(14\)70379-1](https://doi.org/10.1016/S1470-2045(14)70379-1)

Originally published at:

Stupp, R; Hegi, M E; Gorlia, T; et al; Kim, C Y; Nabors, L B; Reardon, D A; van den Bent, M J; Hicking, C; Markivskyy, A; Picard, M; Weller, M (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncology*, 15(10):1100-1108.

DOI: [https://doi.org/10.1016/S1470-2045\(14\)70379-1](https://doi.org/10.1016/S1470-2045(14)70379-1)

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated *O*⁶-methylguanine-DNA methyltransferase (MGMT) promoter: final results of the multicentre, randomised, open-label, controlled, phase 3 CENTRIC (EORTC 26071-22072) study

Prof Roger Stupp, MD,^{1,2} Monika E. Hegi, PhD,² Thierry Gorlia, PhD,³ Sara C. Erridge, MD,⁴ James Perry, MD,⁵ Prof Yong-Kil Hong, MD,⁶ Kenneth D. Aldape, MD,⁷ Benoit Lhermitte, MD,² Prof Torsten Pietsch, MD,⁸ Prof Danica Grujicic, MD,⁹ Prof Joachim Peter Steinbach, MD,¹⁰ Prof Wolfgang Wick, MD,¹¹ Prof Rafał Tarnawski, MD,¹² Prof Do-Hyun Nam, MD,¹³ Prof Peter Hau, MD,¹⁴ Astrid Weyerbrock, MD,¹⁵ Prof Martin JB Taphoorn, MD,¹⁶ Chiung-Chyi Shen, MD,¹⁷ Nalini Rao, MD,¹⁸ László Thurzo, MD,¹⁹ Ulrich Herrlinger, MD,⁸ Tejpal Gupta, MD,²⁰ Prof Rolf-Dieter Kortmann, MD,²¹ Krystyna Adamska, MD,²² Catherine McBain, MD,²³ Alba A. Brandes, MD,²⁴ Prof Joerg Christian Tonn, MD,²⁵ Oliver Schnell, MD,²⁵ Prof Thomas Wiegel, MD,²⁶ Chae-Yong Kim, MD,²⁷ Louis Burt Nabors, MD,²⁸ David A. Reardon, MD,²⁹ Prof Martin J. van den Bent, MD,³⁰ Christine Hicking, MSc,³¹ Andriy Markivskyy, MD,³¹ Martin Picard, PhD,³¹ and Prof Michael Weller, MD,¹ on behalf of European Organisation for Research and Treatment of Cancer (EORTC), the Canadian Brain Tumor Consortium, and the CENTRIC study team.

¹UniversitätsSpital Zürich, Zurich, Switzerland; ²Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; ³EORTC Data Centre, Brussels, Belgium; ⁴Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, UK; ⁵Sunnybrook Health Sciences Centre, Toronto, ON, Canada; ⁶The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea; ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁸Universität Bonn, Bonn, Germany; ⁹Clinic for Neurosurgery, Clinical Center Serbia and Medical Faculty University of Belgrade, Belgrade, Serbia; ¹⁰Klinikum der J.W. Goethe Universität Frankfurt, Frankfurt, Germany; ¹¹Heidelberg University Medical Center & German Cancer Research Center, Heidelberg, Germany; ¹²Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, Gliwice, Poland; ¹³Samsung Medical Center, Sungkyunkwan Univ School of Medicine, Seoul, Korea; ¹⁴Universitätsklinikum Regensburg, Regensburg, Germany; ¹⁵Universitätsklinikum Freiburg, Freiburg, Germany; ¹⁶Medical Center Haaglanden, The Hague, The Netherlands; ¹⁷Taichung Veterans General Hospital, Taichung, Taiwan; ¹⁸Bangalore Institute of Oncology, Bangalore, India; ¹⁹Szegedi Tudományegyetem, Szeged, Hungary; ²⁰Tata Memorial Centre, Navi Mumbai, India; ²¹Universitätsklinikum Leipzig, Leipzig, Germany; ²²Greater Poland Cancer Centre, Poznań, Poland; ²³The Christie NHS FT, Manchester, UK; ²⁴Medical Oncology Department, AUSL – IRCCS Institute of Neurological Sciences, Bologna, Italy; ²⁵Klinikum der Universität München, München, Germany; ²⁶University Hospital Ulm, Ulm, Germany; ²⁷SNU Bundang Cancer

Hospital, Seoul, South Korea, Korea; ²⁸University of Alabama at Birmingham, Birmingham, AL, USA; ²⁹Dana-Farber Cancer Institute, Boston, MA, USA; ³⁰Erasmus MC-Cancer Institute, Rotterdam, The Netherlands; ³¹Merck KGaA, Darmstadt, Germany.

Corresponding author: Professor Roger Stupp

Address: Department of Oncology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland

Phone: +41 44 255 97 79

Fax: +41 44 255 97 80

Email: Roger.Stupp@usz.ch

Word count (body of the manuscript): 3459

Reference count: 33

Abstract

Background: Cilengitide is a selective $\alpha v\beta 3$ and $\alpha v\beta 5$ integrin inhibitor. Phase 2 trial data suggested antitumour activity of cilengitide as a single agent in recurrent glioblastoma and in combination with standard temozolomide (TMZ) chemoradiotherapy (TMZ/RT→TMZ) in newly diagnosed glioblastoma, particularly in tumours with methylated *MGMT* promoter.

Methods: This multicentre, open-label, phase 3 study (NCT00689221) investigated the efficacy of cilengitide in patients with newly diagnosed, histologically proven supratentorial glioblastoma with methylated *MGMT* status. After stratification for prognostic Radiation Therapy Oncology Group recursive partitioning analysis class and geographic region, patients were centrally randomised 1:1 to receive TMZ/RT→TMZ with cilengitide 2000 mg i.v. twice-weekly (cilengitide arm) or TMZ/RT→TMZ alone (control arm). Maintenance TMZ was given for up to 6 cycles, cilengitide was administered for up to 18 months, or until disease progression or unacceptable toxicity. The primary endpoint was overall survival. Secondary endpoints included progression-free survival (PFS), and safety. Outcome was analysed on intent-to-treat basis.

Findings: Overall, 3471 patients were screened. Of these, 3060 had tumour *MGMT* status tested; 926 patients had a methylated *MGMT* promoter, of which 545 patients (median age, 58 years) were randomised to cilengitide (n=272) or control arm (n=273). Median survival was 26.3 months in both arms (HR, 1.02; 95% CI, 0.81–1.29; p=0.86). PFS assessed by the Independent Review Committee was 10.6 months in the cilengitide arm and 7.9 months in the control arm (HR, 0.92; 95% CI, 0.75–1.12; p=0.41). Investigator assessed PFS was 13.5 months in the cilengitide arm and 10.7 months in the control arm (HR, 0.93; 95% CI, 0.76–1.13; p=0.46). None of the predefined clinical subgroups showed a benefit from cilengitide. Treatment was generally well tolerated, no added toxicity was observed with cilengitide. Most commonly reported (>5%) grade ≥ 3 adverse events in the cilengitide and control arm, respectively, included lymphopaenia (n=31 vs n=26), thrombocytopaenia (n=28 vs n=46); neutropaenia (n=19 vs n=24), leukopaenia (n=18 vs n=20), and convulsion (n=14 vs n=15).

Interpretation: The addition of cilengitide to standard TMZ/RT→TMZ did not improve outcome and cilengitide will not be further developed as an anticancer agent. Nevertheless, integrins remain a potential treatment target for glioblastoma.

Funding: Merck KGaA, Darmstadt, Germany.

Introduction

Glioblastoma is the most common histological subtype of primary malignant brain tumours, with an annual incidence of approximately 3/100,000.¹ Glioblastomas are also the most aggressive form of primary brain tumours, with a dismal median survival <12 months in population-based studies, and median survival of 15–17 months in clinical trials.^{2–4} The current standard treatment for patients with newly diagnosed glioblastoma consists of surgery followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ/RT→TMZ).^{2,5} Other chemotherapy agents demonstrated little activity due to inherent resistance of glioblastoma cells against most cytotoxic agents, or the inability of the agents to cross an intact blood-brain barrier and reach their target.^{6,7}

The DNA repair protein O⁶-methylguanine-DNA methyltransferase (MGMT) is an important prognostic factor in glioblastoma; its presence has been associated with inferior survival and resistance to alkylating chemotherapy.⁸ Epigenetic silencing of the *MGMT* gene by promoter methylation may lead to it subsequently being unable to protect tumours from cytotoxic damage induced by TMZ and thus predict benefit from TMZ chemotherapy.⁹ In a pivotal randomised trial investigating the value of TMZ added to RT in patients with glioblastoma, median survival in patients with methylated *MGMT* promoter was increased from 15.3 months with RT alone to 21.7 months with RT and TMZ.¹⁰ However, patients with unmethylated *MGMT* promoter in the tumour showed only a marginal benefit from RT and TMZ treatment, with a median survival of 12.7 vs 11.8 months.

Although glioblastomas very rarely metastasise, local recurrence at the edge of resection but also at distant locations within the brain is frequent. Glioblastoma cells are characterised by high motility and invasiveness, requiring complex cell-matrix interactions.¹¹ Integrins are a family of cell-cell and cell-extracellular matrix adhesion molecules, involved in a variety of cellular processes, such as cell survival, proliferation, migration, invasion, and angiogenesis, and thus can support tumour development.¹² In particular $\alpha\text{v}\beta 3$ and $\alpha\text{v}\beta 5$ integrins are considered key mediators of crosstalk between tumour cells and the brain microenvironment in glioblastoma and are overexpressed on

tumour cells and vasculature.^{13–15} Therefore, targeting integrins and the tumour microenvironment is considered a promising therapeutic strategy in glioblastoma.^{15,16}

Cilengitide is a selective inhibitor of $\alpha v\beta 3$ and $\alpha v\beta 5$ integrins.¹⁷ In phase 1/2 studies in patients with recurrent or newly diagnosed glioblastoma, cilengitide alone or in combination with TMZ/RT→TMZ was well tolerated and showed potential antitumour activity.^{18–22} In a multicentre phase 1/2 study of cilengitide added to standard TMZ/RT→TMZ in patients with newly diagnosed glioblastoma, survival analyses indicated improved outcome compared with historical controls in patients with methylated *MGMT* gene promoter in the tumour, suggestive of synergy between cilengitide and TMZ chemotherapy in chemosensitive tumours.²⁰ Patients with and without *MGMT* promoter methylation had median progression-free survival (PFS) of 13·4 and 3·4 months, and a median overall survival of 23·2 and 13·1 months, respectively.²⁰ Furthermore, two randomised phase 2 studies demonstrated improved survival for glioblastoma patients treated with higher (2000 mg) versus lower (500 mg) dose of cilengitide, in both the newly diagnosed and recurrent setting.^{19,21} Preclinical models also demonstrated synergistic activity of cilengitide and irradiation.²³ Thus, we embarked on the randomised phase 3 trial reported here, restricting eligibility to a subgroup of patients with glioblastoma with methylated *MGMT* promoter. The investigation of patients with an unmethylated *MGMT* promoter in the tumour was subject of an exploratory phase 2 study (CORE) initiated shortly after CENTRIC.²⁴

Methods

Study design and treatment

This was a global, multicentre, randomised, controlled, open-label, phase 3 study (NCT00689221). Patients were recruited at over 200 study sites in 25 countries worldwide. Prior to randomisation and after informed consent, an independent pathology review was performed and *MGMT* promoter methylation status of the tumour was centrally determined by licensed laboratories of MDxHealth (Herstal, Belgium) using quantitative methylation-specific polymerase chain reaction (PCR) basically as described previously.²⁵ In brief, DNA was isolated from formalin-fixed, paraffin-embedded tumour samples using macro-dissected sections; DNA was modified with sodium bisulfite and subjected to methylation-specific PCR using β -actin as a reference gene (*ACTB*). Patients were considered *MGMT* methylated when the ratio of *MGMT* to *ACTB* was 2.0 or more, calculated as (methylated *MGMT*/*ACTB*) \times 1000; the cut-off corresponding to the established nadir that separates methylated from unmethylated.²⁶ A minimum of 1250 copies of *ACTB* were required for a valid result, unless the copy number for methylated *MGMT* was ten or more, which was scored as *MGMT* methylated.

Eligible patients were subsequently randomly assigned 1:1 to receive either standard TMZ/RT \rightarrow TMZ alone, or with added cilengitide (standard dose of 2000 mg i.v. twice weekly on Days 1 and 4, beginning at week 1)³ (**Figure 1**). RT consisted of 3D conformal RT and was given at 2 Gy per fraction, 5 days/week, for up to 6 weeks and a total of 60 Gy; TMZ 75 mg/m² was administered orally 7 days/week throughout RT, thereafter, starting 4 weeks after the end of RT (week 11) TMZ 150–200 mg/m² was administered for 5 consecutive days every 4 weeks for 6 cycles.³ Cilengitide was to be continued for up to 18 months or until disease progression (PD) or unacceptable toxicity. In case of first occurrence of an unacceptable toxicity considered as study drug-related, cilengitide treatment was to be suspended until recovery from the adverse event (AE) to grade \leq 2. Thereafter, administration could be restarted at the investigator's discretion at a dose of 500 mg, and gradually increased in weekly intervals up to 2000 mg. Cilengitide treatment was to be discontinued

permanently if the same severe toxicity recurred. Crossover from the control to the cilengitide arm was not allowed. Cilengitide was administered as 1-hour i.v. infusion starting 4 hours before RT; TMZ was given orally within 2 hours after completion of cilengitide infusion and at least 1 hour before RT. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation note for good clinical practice (Topic E6, 1996), and applicable regulatory requirements. Study protocol and patient information sheet were approved by the Institutional Review Boards or Independent Ethics Committees of the participating institutions and competent authorities according to country-specific regulations.

Randomisation and masking

Randomisation (1:1) was performed centrally using an interactive voice response system. Patients were stratified in blocks according to geographic region (ie, Europe, North America, and Rest of World) and Radiation Therapy Oncology Group recursive partitioning analysis class. As this was an open-label study, no blinding procedures were applied.

Key patient eligibility criteria

Patients aged ≥ 18 years with newly diagnosed, histologically confirmed supratentorial glioblastoma (WHO Grade IV), centrally determined methylated *MGMT* status, and with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 were eligible. Additional inclusion criteria were: written informed consent; available tumour tissue from surgery or open biopsy (stereotactic biopsy was not allowed) for *MGMT* promoter methylation status analysis and central pathology review; gadolinium-enhanced (Gd) MRI performed within 48 hours postsurgery, or alternatively, Gd-MRI performed before randomisation; stable or decreasing steroid doses for ≥ 5 days prior to randomisation; and adequate haematological, renal, and liver function. Key exclusion criteria were prior chemotherapy within the last 5 years, prior RT of the head (except for low-dose RT for tinea capitis), treatment with other investigational agents 30 days before first dose of cilengitide, and prior systemic antiangiogenic therapy; history of coagulation disorder associated with bleeding or

recurrent thromboembolic events; placement of carmustine wafers (Gliadel®) at surgery; history of malignancy within the last 5 years (except curatively treated cervical carcinoma *in situ* or basal cell carcinoma of the skin); clinically manifest cardiovascular insufficiency (NYHA III, IV) or history of myocardial infarction during the past 6 months, and uncontrolled arterial hypertension.

Study endpoints

The primary endpoint was overall survival. Secondary endpoints included PFS and safety.

Outcome measures and statistical analyses

Overall survival was defined as time from randomisation until death; PFS was defined as duration from randomisation until first observation of PD or death from any cause. PFS was assessed locally by investigators based on Gd-MRI and according to the Macdonald criteria 4 weeks after RT, and 18, 26, and 34 weeks after randomisation as well as every 12 weeks thereafter during the follow-up phase. In case of suspected pseudoprogression investigators were advised to continue treatment per protocol and repeat imaging after 1-2 months. All imaging was reviewed at the end of study recruitment by an Independent Review Committee in a blinded manner. For this external review the recently (after this study's protocol initiation) developed and recommended Response Assessment in Neuro-Oncology (RANO) rather than the Macdonald criteria were used.²⁷ Overall survival and PFS were estimated using the Kaplan-Meier method. Treatment arms were compared using log-rank test stratified for randomisation strata. A Cox proportional hazards model with stratification according to randomisation strata was used to calculate treatment HR and 95% CIs. No check of proportional hazards (PH) assumptions was planned per protocol. Sensitivity analyses were performed unstratified and for the per-protocol set.

AEs were coded according to the Medical Dictionary for Regulatory Activities version 15.0, and their severity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. All outcome analyses were performed on the intention-to-treat (ITT) population;

safety was assessed on patients treated with at least one dose of cilengitide or who were exposed to RT or TMZ (safety population).

The study sample size was based on the assumption of a median overall survival of 23 months for the control group, a hazard ratio (HR) for the difference in overall survival between the experimental and control arms of 0.71, power of 80%, two-sided significance level of 5%, and accrual of 24 months. Based on these assumptions, the target number of events was 266, expected after 21 month follow-up, and planned sample size was 504 patients or 252 patients per arm. One formal interim analysis for futility was planned after observing 25% of planned maximal number of events. All statistical analyses were independently performed on mature data with a median follow-up of 29 months (interquartile range [IQR], 25–35 months) by both statisticians at Merck KGaA, Darmstadt, Germany, and at the European Organisation for Research and Treatment of Cancer (EORTC) using SAS® software version 9.1 or later.

Role of the funding source

This study was funded by Merck KGaA, Darmstadt, Germany. Study design, data analysis, and data interpretation were performed collaboratively by the principal investigators, EORTC, and the Merck study team. The Steering Committee oversaw the study. The principal investigators (RS, MW) had full access to and reviewed all data, and had final responsibility for the decision to submit for publication. Data collection was performed by a clinical research organisation; the database remained blinded to primary outcome variables for all parties until final analysis.

Results

Overall, 3471 patients were registered and screened for eligibility; of these, 3060 patients were assessed for *MGMT* methylation status. A total of 926 patients were found to have glioblastoma with *MGMT* gene promoter methylation, including 382 patients who did not continue to randomisation for reasons as depicted in **Figure 2**. A total of 545 patients were randomised from October 2008 through May 2011 and constituted the ITT population: 272 patients were scheduled to receive cilengitide twice-weekly in addition to standard TMZ/RT→TMZ (cilengitide arm) and 273 were to receive TMZ/RT→TMZ alone (control arm). The median duration from operation or biopsy to randomisation was 4.4 weeks (IQR, 3.7–5.4 weeks); the median time from surgery to start of RT was 6.2 weeks (IQR, 5.3–7.0 weeks) in the cilengitide arm and 5.4 weeks (IQR, 4.6–6.1 weeks) in the control arm (cilengitide treatment was to begin one week before RT). Patient baseline and demographic characteristics were well balanced across treatment arms; they are summarised in **Table 1**. Overall, 263 patients in the cilengitide arm, and 258 patients in the control arm, received at least one dose of study medication (safety population). The main reasons for discontinuing treatment in the cilengitide arm were PD (n=157), AE (n=22), and other (n=54), and in the control arm, PD (n=153), AE (n=26), and other (n=57). A total of 152 and 151 patients in the cilengitide and the control arm, respectively, received a further line of therapy following documented PD (**Supplementary Table 1**).

Patients in the cilengitide arm (safety population) received cilengitide for a mean (\pm SD) of 55.6 (\pm 41.6) weeks, with a mean dose intensity of 3782 (\pm 481) mg/week; 216 patients (82%) received \geq 90% of the planned cilengitide dose. Overall, 237 patients (90%) in the cilengitide arm received \geq 90% of the planned TMZ dose, comparable to 237 patients (92%) in the control group. Furthermore, 199 and 197 patients (76% and 76%) received \geq 90% of the planned dose of RT, in the cilengitide and control arms, respectively.

Median overall survival was 26·3 months (95% CI, 24–29) in the cilengitide arm and 26·3 months (95% CI, 24–35) in the control arm (282 deaths; HR, 1·02; 95% CI, 0·81–1·29; $p=0·86$; **Figure 3A**). The 2-year survival rate did not differ between treatment arms (56% in both; 95% CI, 49%–61% for the cilengitide arm, 49%–62% for the control arm). Overall survival was similar in the two treatment arms irrespective of stratification according to baseline demographic characteristics and prognostic factors (**Figure 3B**). Median PFS as assessed by the investigator was 13·5 months (95% CI, 10·8–15·9) in the cilengitide arm and 10·7 months (95% CI, 8·1–13·3) in the control arm (388 PFS events; HR, 0·93; 95% CI, 0·76–1·13; $p=0·46$; **Figure 4A**). The independent radiological review committee determined progression on average one assessment time point earlier in both arms, with a median of PFS 10·6 months (95% CI, 8·2–13·4) and 7·9 months (95% CI, 5·9–12·5), respectively, in the cilengitide arm and control arm (389 PFS events; HR, 0·92; 95% CI, 0·75–1·12; $p=0·41$; **Figure 4B**). Additionally, no benefit was observed in overall survival or PFS in the predefined patient subgroups with the addition of cilengitide to TMZ/RT→TMZ.

Safety

Almost all patients experienced some treatment-emergent AEs (TEAEs) (**Supplementary Table 2**). Grade 3 or 4 TEAEs were observed in over half the patients, but there was no difference between the treatment arms (169 patients [64%] in the cilengitide arm and 158 [61%] in the control arm). The most common TEAEs (any grade and grade ≥ 3) are summarised in **Table 2**. Grade 3 or 4 thromboembolic events occurred more frequently in the cilengitide arm (35 patients [13%]) compared with the control arm (23 patients [9%]), but still within the expected range. Grade 3 or 4 haemorrhages were similar in both arms (4 patients [2%] each per arm). At least one serious AE was reported by 138 patients (53%) in the cilengitide arm versus 115 patients (45%) in the control arm. In the cilengitide arm, 11 patients (4%) experienced TEAEs leading to death compared with 9 patients (3%) in the control arm. Three patient deaths (1%) in each study arm were considered treatment related (**Supplementary Table 3**). In the cilengitide arm, two patients (1%) died of pulmonary embolism, and one (<1%) of aspiration pneumonia; none of these patients had myelosuppression. In

the control arm, one (<1%) patient died of pancytopenia and pneumonia, one (<1%) of pneumonia after restarting TMZ following pancytopenia, and one (<1%) of septic shock without myelosuppression. Pneumocystis infections were not observed.

Discussion

This large, prospective, phase 3 trial investigating the novel and first-in-class integrin inhibitor cilengitide as antitumour therapy in combination with standard chemoradiotherapy failed to demonstrate improved outcome. Neither PFS nor overall survival were significantly prolonged, and a HR of 1.02 for overall survival suggests absence of any activity. The median overall survival of 26.3 months observed in both treatment arms is consistent with prior reports and experience in this *MGMT*-methylated glioblastoma patient population who have undergone gross total or partial tumour resection. Safety and tolerability of cilengitide in combination with standard treatment were confirmed in this large multicentre trial; there was no indication of increased treatment-emergent toxicity with the addition of cilengitide.

These results raise the question of why the antitumour activity of cilengitide observed in prior phase 2 studies was not seen in this trial. Indeed, the extensive phase 1 and phase 2 clinical development programme repeatedly demonstrated objective and durable responses in patients with recurrent glioblastoma,^{18,19} provided evidence for the drug reaching the tumour tissue,²² and indicated a dose-dependent trend for a potential improved overall survival when comparing a higher and lower cilengitide dose in randomised trials for recurrent and newly diagnosed glioblastoma patients.^{19,21} At the same time, cilengitide early development trials used either a lower dose (500 mg) or compared different dosing regimens (500 vs 2000 mg cilengitide), but were conducted without standard of care controls, and their comparisons were based on historical data,¹⁸⁻²¹ which is in contrast to CENTRIC, where a control arm was included for comparison.

Cilengitide may induce some normalisation of the blood-brain barrier by itself, thus suggesting treatment response on imaging. Considering the short serum half-life of cilengitide of about 2–4 hours,^{18–20,28} a schedule of continuous i.v. administration rather than a twice-weekly bolus may have been more appropriate. Although low concentrations of cilengitide have been linked to proangiogenic activity in experimental tumour models and altered $\alpha v\beta 3$ integrin and vascular

endothelial growth factor receptor-2 trafficking,²⁹ we have previously argued that these experimental conditions probably do not reflect the clinical scenario of administering 2000 mg/m² cilengitide.³⁰ This would be consistent with the observation that the cilengitide arm was comparable to the control arms in terms of safety, and no detrimental effect was observed in any subgroup analysed in the CENTRIC trial. Functional imaging demonstrating successful tumour targeting may also have been helpful.³¹

Numerous other agents were explored over the last decade in order to improve outcome of glioblastoma patients. Inhibition of angiogenesis remains a prime treatment target. Similarly to cilengitide, randomised trials of bevacizumab added to standard TMZ/RT in newly diagnosed glioblastoma failed to prolong overall survival, although PFS was prolonged.^{32,33} These repeatedly failed efforts underscore the complexity of this tumour type, and warrant better preclinical models and investigation of combined target inhibition and improved collaboration. More extensive and ideally controlled early phase clinical trials are needed, and a critical appraisal of the results required before moving into definitive large-scale phase 3 evaluations. Despite the negative outcome of the here reported trial, targeting integrins remains a theoretically attractive target, as they are involved in essential aspects of malignancy such as angiogenesis, migration, and invasion and their patterns in malignancies differ from those of their parent tissues, potentially allowing selective targeting.¹⁶

In the CENTRIC trial almost 3500 patients with a rare disease¹ were screened and molecularly assessed for eligibility over a 2-year period. This underscores the urgent need for novel and better treatments for patients suffering from glioblastoma, and shows a substantial number of patients are affected by a disease often excluded from clinical drug development programmes. Potentially detrimental treatment delays have been a concern when seeking to molecularly characterise tumour types before allocation to specific treatments. In our trial the median time to treatment start was 5–6 weeks, well within the accepted range of up to 7 weeks.² Similarly, the recently reported AVAglio study indicated that 96% of all patients started treatment within 4–7 weeks³² and in a trial evaluating treatments for elderly patients the median time to start of RT was 40–46 days.²⁶ Other publications

do not report the time interval between surgery and treatment start.³³ In our trial there was no indication that the time interval between initial diagnosis and treatment start influenced outcome.

A notable aspect of this trial was the unique collaboration of industry and academia. The trial was designed by academic teams of the EORTC and the Canadian Brain Tumor Consortium, in close collaboration with the manufacturer of cilengitide, Merck KGaA, Darmstadt, Germany. As this trial was designed as a registration trial of an entirely novel compound and a companion diagnostic, study sponsorship and management was coordinated by Merck KGaA, but investigators and representatives of the EORTC held the majority positions in the Steering Committee and were intimately involved in the study conduct and data interpretation. Data of all randomised patients were reviewed by the principal investigators, and statistical analyses were performed independently by the study teams at Merck and EORTC. Moreover, this close collaboration now allows assured long-term follow-up and expanded analyses of molecular tumour characteristics by EORTC-based platforms. While Merck KGaA is not pursuing further development of this compound, it continues to support the collaboration.

This trial demonstrated the feasibility of performing upfront central histological review and molecular testing with no significant delay in an international multicentre setting. This is a prerequisite for further drug development towards personalised medicine.

Systematic review

We screened PubMed and abstracts presented at clinical oncology meetings for reports of clinical trials investigating novel agents for newly diagnosed glioblastoma. Apart from combined chemoradiotherapy, the current standard treatment of care, the review revealed that there are no established alternative treatment options available for these patients, although several targeted agents and angiogenesis inhibitors are being investigated. Cilengitide showed activity in early phase trials, and efficacy was believed best when combined with other active treatments. Patients with a methylated *MGMT* promoter were found to have a better outcome with current treatments, thus this trial molecularly preselected patients with *MGMT* methylation status. In a joint development by academia led by EORTC and the manufacturer this randomised comparative phase 3 trial was designed and conducted

Interpretation

Despite the encouraging results from preclinical and prior phase 1 and 2 studies, the results from this randomised phase 3 trial failed to demonstrate any improvement in outcome of glioblastoma patients when cilengitide is added to the standard chemoradiotherapy. The failure of cilengitide to improve outcomes in newly diagnosed glioblastoma highlights the pitfalls of conducting phase 3 trials based on limited phase 2 data and represents a drawback for integrin inhibition as a novel approach to cancer therapy. Only little progress in the treatment of glioblastoma has been made over the last decade.

The impressive international participation in the screening of over 3000 patients in this trial underscores the need for better treatments. We demonstrated that upfront molecular analyses and patient population enrichment is feasible. Successful collaboration between academia and industry

performing a large clinical trial jointly while allowing for independence of the partners, separate statistical analyses and long-term follow-up has been shown.

Acknowledgements

The authors would like to thank patients for their trust and participation, and their family members for the provided support and care. The authors are grateful to the many dedicated investigators, nurses, data-managers and other collaborators at the participating sites. They want to thank Robert Janzer (deceased) who also performed the central pathology review. Furthermore, the authors want to thank the members of the independent data monitoring committee, Prof Jan C. Buckner, Prof Jean-Pierre Armand, Prof Sally Stenning, Prof Sebastian Harder, and Dr Werner Holtbrügge. Finally, the authors would like to acknowledge the excellent collaboration of the teams at Merck KGaA, Quintiles, MDxHealth, the Canadian Brain Tumor Consortium, and the EORTC.

Editorial and medical writing assistance was provided by Anna Hooijkaas, PhD, TRM Oncology, The Hague, The Netherlands, funded by Merck KGaA, Darmstadt, Germany.

Individual contribution of each author

RS*: Study oversight, study design, data collection, data review and interpretation, manuscript writing

MEH*: Oversight molecular testing, study design, data collection, data review and interpretation, manuscript writing

TG*: Study design, data collection, data analysis, data interpretation, manuscript writing

SE*: Radiation therapy oversight, study design, data collection, data interpretation, manuscript writing

JP*: Study design, data collection, data interpretation, manuscript writing

YKH*: Study design, data collection, data interpretation, manuscript writing

KDA: Pathology review, manuscript writing

BL: Pathology review, manuscript writing

TP: Pathology review, manuscript writing

DG: Data collection and interpretation, patient recruitment, manuscript writing

JPS: Data collection, data interpretation, manuscript writing

WW*: Data collection, manuscript writing

RT: Data collection, manuscript writing

DHN: Data collection, manuscript writing

PH: Data collection, manuscript writing

AW: Data collection, manuscript writing

MJBT: Data collection and interpretation, manuscript writing

CCS: Data collection, manuscript writing

NR: Data collection, manuscript writing

LT: Data collection, manuscript writing

UH: Data collection, manuscript writing

TG: Data collection, manuscript writing

RDK: Data collection, manuscript writing

KA: Data collection, manuscript writing

CMcB: Data collection, manuscript writing

AAB: Data collection, manuscript writing

JCT: Data collection, manuscript writing

OS: Data collection, manuscript writing

TW: Data collection, manuscript writing

CYK: Data collection, manuscript writing

LBN: Study design, data collection, data interpretation, manuscript writing

DAR*: Study design, data collection, data interpretation, manuscript writing

MJvdB*: Study design, data collection, manuscript writing

CH: Study design, data collection, data analysis, data interpretation, manuscript writing

AM: Medical and scientific study support, data collection, data interpretation, manuscript writing

MP*: Study oversight, study design, data collection, data review and interpretation, manuscript writing

MW*: Study oversight, study design, data collection, data review and interpretation, manuscript writing

*Indicates steering committee member.

Conflicts of interest

RS: expenses in relationship with study from Merck KGaA; advisory board for Roche, MSD/Merck & Co; and Novartis.

MEH: service contract from Merck Serono; grant from MDxHealth; personal fees from MSD; advisory fees from Roche and MDxHealth.

SE: grant from Merck KGaA.

TP: travel grant, honoraria, and payment for reference pathology from Merck, Roche, and Antisense Pharma.

JPS: advisory board for Roche and Mundipharma; personal fees from Medac; grant for independent scientific project from Merck.

WW: grants from Roche, MSD, Eli Lilly, Boehringer Ingelheim, and Apogenix; personal fees from Roche and MSD.

RT: personal fees from Merck KGaA.

DHN: research funding from Merck Serono, Eli Lilly, Oncosynergy, and Regulus.

AW: personal fees from Roche.

MJBT: personal fees from Hoffman La Roche.

UH: consultancy role for Roche, personal fees from Roche, Medac, Mundipharma, research funding from Roche, Medac.

TG: grant from Merck KGaA.

KA: personal fees from Quintiles Eastern Holding.

CMcB: personal fees from Roche.

JCT: personal fees from Merck Serono, Roche, and Medac; grants from the German Cancer Foundation (Krebshilfe), German Research Foundation (DFG), and the German Ministry of Research and Technology (BMBF).

OS: personal fees from Roche.

DAR: personal fees from Roche/Genentech, Merck/Schering, EMD Serono, Novartis, Amgen, Stemline Therapeutics, and Momenta Pharmaceuticals.

MJvdB: personal fees from Merck KGaA, Hoffman La Roche, AstraZeneca, Abbvie, and MSD; grants from Hoffman La Roche and Abbvie.

CH: employed by Merck KGaA; owner of stock from Merck KGaA.

AM, MP: employed by Merck KGaA.

MW: consultant or advisory role for Isarna, Merck Serono, Roche, and Magforce; personal fees from Merck Serono, Roche, MSD, and Magforce; research funding from Bayer, Merck Serono, Roche, MSD, and Isarna.

JP, YKH, KDA, BL, DG, PH, CCS, NR, LT, RDK, AAB, TW, CYK, LBN: No conflicts of interest to disclose.

References

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. *Neuro-Oncol* 2012;**14**:v1–49.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;**352**:987–96.
3. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. *J Neurooncol* 2012;**107**:359–64.
4. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. *J Clin Oncol* 2013;**31**:4085–91
5. Weller M, Van den Bent M, Hopkins K, et al., for the European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO Guideline on the Diagnosis and Treatment of Malignant Glioma. *Lancet Oncol* 2014; in press.
6. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. *Expert Rev Mol Med* 2011;**13**:e17.
7. Haar CP, Hebbar P, Wallace GC 4th, et al. Drug resistance in glioblastoma: a mini review. *Neurochem Res* 2012;**37**:1192–200.
8. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. *J Clin Oncol* 1998;**16**:3310–5.
9. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. *Clin Cancer Res* 2004;**15**:1871–4.

10. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;**352**:997–1003.
11. Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. *J Natl Cancer Inst* 2007;**99**:1583–93.
12. Stupack DG. The biology of integrins. *Oncology (Williston Park)* 2007;**21**:6–12.
13. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. *Neurosurgery* 2001;**49**:380–9.
14. Schnell O, Krebs B, Wagner E, et al. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. *Brain Pathol* 2008;**18**:378–86.
15. Roth P, Silginer M, Goodman SL, et al. Integrin control of the transforming growth factor- β pathway in glioblastoma. *Brain* 2013;**136**:564–76.
16. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. *Nat Rev Cancer* 2010;**10**:9–22.
17. Smith JW. Cilengitide Merck. *Curr Opin Investig Drugs* 2003;**4**:741–5.
18. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. *J Clin Oncol* 2007;**25**:1651–7.
19. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. *J Clin Oncol* 2008;**26**:5610–7.
20. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *J Clin Oncol* 2010;**28**:2712–8.

21. Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). *Cancer* 2012;**118**:5601–7.
22. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. *J Neurooncol* 2012;**106**:147–53.
23. Mikkelsen T, Brodie C, Finniss S et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. *Int J Cancer* 2009;**124**:2719–27.
24. Nabors LB, Fink KL, Mikkelsen T, et al. Cilengitide in combination with standard treatment for patients with newly diagnosed glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the open-label, controlled, randomized phase II CORE study. *Neurooncol* 2013;**15**:viii75–84. Abstract MR-021.
25. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. *J Mol Diagn* 2008;**10**:332–7.
26. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. *Lancet Oncol* 2012;**9**:916–26.
27. Wen YP, Macdonald DR, Reardon DA, et al. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. *J Clin Oncol* 2010;**28**:1963–72.
28. Hariharan S, Gustafson D, Holden S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. *Ann Oncol* 2007;**18**:1400–7.

29. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. *Nat Med* 2009;15:392-400.
30. Weller M, Reardon D, Nabors B, et al. Will integrin inhibitors have proangiogenic effects in the clinic? *Nat Med*. 2009;15:726; author reply 727.
31. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. *Neuro Oncol* 2009;11:861–70.
32. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med* 2014;370:709–22.
33. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med*.2014;370(8):699-708.

Tables

Table 1. Patient baseline characteristics and demographics (ITT population)

	Cilengitide arm (n=272)	Control arm (n=273)
Age (years)		
Median (range)	58 (22–81)	58 (22–79)
Sex, n (%)		
Male	148 (54)	143 (52)
Region, n (%)		
North America	32 (12)	33 (12)
Europe	185 (68)	183 (67)
Rest of the World	55 (20)	57 (21)
ECOG performance status, n (%)		
0	156 (57)	151 (55)
≥1	116 (43)	121 (44)
Missing	0 (0)	1 (<1)
RPA class, n (%)		
III	44 (16)	42 (15)
IV	184 (68)	171 (63)
V	43 (16)	55 (20)
Missing	1 (<1)	5 (2)
MMSE, n (%)		
<27	45 (17)	61 (22)
≥27	225 (83)	207 (76)
Missing	2 (<1)	5 (2)
Extent of resection, n (%)		
Gross total resection	132 (49)	137 (50)

Partial resection	131 (48)	127 (47)
Biopsy	9 (3)	7 (3)
Missing	0 (0)	2 (1)
Antiepileptics (baseline), n (%)		
EIAED	54 (20)	57 (21)
Non-EIAED only	99 (36)	121 (44)
None	119 (44)	94 (34)
Steroids (baseline), n (%)		
Yes	103 (38)	113 (41)
Time from diagnosis to randomisation (weeks)		
Median (range)	4.1 (0.3–9.0)	4.0 (1.4–7.4)
Time from diagnosis to start of RT (weeks)		
Median (range)	6.2 (5.3–7.0)	5.4 (4.6–6.1)

ITT, intention-to-treat; ECOG, Eastern Cooperative Oncology Group; RPA, recursive partitioning analysis; MMSE, Mini-Mental State Examination; EIAED, enzyme-inducing antiepileptic drugs; RT, radiotherapy.

Table 2. Most common TEAEs by preferred term (safety population; any grade observed in at least 10% of patients or grade ≥ 3 reported in at least 2% of patients)*

Preferred term, n (%)	Cilengitide arm (n=263)			Control arm (n=258)		
	Any grade	Grade 3	Grade 4	Any grade	Grade 3	Grade 4
Nausea	130 (49)	3 (1)	-	127 (49)	5 (2)	-
Headache	119 (45)	10 (4)	-	88 (34)	8 (3)	-
Fatigue	102 (39)	14 (5)	-	85 (33)	8 (3)	-
Constipation	102 (39)	2 (1)	-	78 (30)	-	-
Vomiting	80 (30)	3 (1)	-	87 (34)	9 (3)	-
Alopecia	70 (27)	2 (1)	-	70 (27)	1 (<1)	-
Thrombocytopaenia	62 (24)	15 (6)	13 (5)	70 (27)	20 (8)	26 (10)
Convulsion	57 (22)	9 (3)	5 (2)	28 (11)	13 (5)	2 (1)
Decreased appetite	54 (21)	1 (<1)	-	45 (17)	-	-
Cough	51 (19)	1 (<1)	-	23 (9)	-	-
Asthaenia	47 (18)	8 (3)	-	21 (8)	3 (1)	-
Lymphopaenia	46 (17)	24 (9)	7 (3)	36 (14)	24 (9)	2 (1)
Diarrhoea	45 (17)	3 (1)	-	20 (8)	2 (1)	-
Dizziness	36 (14)	2 (1)	-	25 (10)	1 (<1)	-
Oedema peripheral	36 (14)	2 (1)	-	24 (9)	1 (<1)	-
Neutropaenia	35 (13)	10 (4)	9 (3)	29 (11)	11 (4)	13 (5)
Insomnia	35 (13)	-	-	24 (9)	-	-
Leukopaenia	33 (13)	13 (5)	5 (2)	33 (13)	11 (4)	9 (3)
Nasopharyngitis	32 (12)	-	-	11 (4)	-	-
Pruritus	32 (12)	2 (1)	-	15 (6)	-	-
Back pain	31 (12)	1 (<1)	-	8 (3)	2 (1)	-
Pyrexia	30 (11)	2 (1)	-	19 (7)	-	-
Rash	28 (11)	1 (<1)	-	19 (7)	1 (<1)	-
Upper respiratory tract infection	28 (11)	-	-	16 (6)	-	-

Memory impairment	27 (10)	1 (<1)	-	18 (7)	1 (<1)	-
Aphasia	25 (10)	6 (2)	-	12 (5)	5 (2)	-
Haemiparesis	21 (8)	11 (4)	1 (<1)	11 (4)	4 (2)	1 (<1)
Alanine aminotransferase	21 (8)	7 (3)	-	17 (7)	4 (2)	-
Aneamia	17 (6)	7 (3)	-	17 (7)	2 (1)	2 (1)
Pneumonia	15 (6)	9 (3)	2 (1)	11 (4)	3 (1)	3 (1)
Peripheral motor neuropathy	14 (5)	9 (3)	-	3 (1)	1 (<1)	-
Hyperglycaemia	13 (5)	11 (4)	-	8 (3)	5 (2)	-
Deep vein thrombosis	13 (5)	10 (4)	-	6 (2)	4 (2)	2 (1)
Lymphocyte count decreased	13 (5)	7 (3)	3 (1)	6 (2)	1 (<1)	1 (<1)
Pulmonary embolism	13 (5)	2 (1)	10 (4)	8 (3)	1 (<1)	6 (2)
Hyponatraemia	14 (5)	4 (2)	2 (1)	8 (3)	7 (3)	-
White blood cell count	1 (<1)	-	-	11 (4)	6 (2)	-


*If a patient experienced more than 1 AE within a preferred term, the patient was counted once in the term.

In this study, grade 5 was not possible to assign to an AE; those AEs were recorded as grade 3 or 4 leading to death (Supplementary Table 3).

AE, adverse events; TEAE, treatment-emergent adverse event.


Figures

Figure 1. Treatment scheme.



MGMT, *O*⁶-methylguanine-DNA methyltransferase; R, randomisation; i.v., intravenous; TMZ, temozolomide; RT, radiotherapy; Gy, Gray.

Figure 2. CONSORT statement diagram.




*Pre-screening for methylation status of the *MGMT* gene promoter.

†Reasons for exclusion as reported by the investigator.

‡1 patient with unmethylated *MGMT* gene promoter was randomised erroneously.

MGMT, *O*⁶-methylguanine-DNA methyltransferase; ICF, informed consent form; ITT, intention-to-treat; TMZ, temozolomide; RT, radiotherapy; CIL, cilengitide.

Figure 3. Kaplan-Meier plot of OS (A) and forest plot (B) detailing OS based on patient demographics (ITT population).




*Stratified HR is displayed in all Kaplan Meier analyses; unstratified HRs are displayed in all subgroup analyses.

HR, hazard ratio; CI, confidence interval; OS, overall survival; TMZ, temozolomide; RT, radiotherapy; CIL, cilengitide; *MGMT*, *O*⁶-methylguanine-DNA methyltransferase; NR, median not yet reached; RPA,


recursive partitioning analysis; ITT, intention-to-treat; ECOG PS, Eastern Cooperative Oncology Group performance status; MMSE, Mini Mental State Examination; EIAED, enzyme-inducing antiepileptic drugs.

Figure 4. PFS as assessed by the investigator (A) and assessed by the IRC (B) (ITT population).



CIL, cilengitide; CI, confidence interval; HR, hazard ratio; ITT, intention-to-treat; PFS, progression-free survival; TMZ, temozolomide; RT, radiotherapy.

Figure 2



Supplementary materials

Supplementary Table 1. Treatment following documented PD (ITT population)

	Cilengitide arm (n=272)	Control arm (n=273)
Patients with documented PD, n (%)	157 (58)	153 (56)
Treatment following documented PD, n (%)		
≥1 Therapy	152 (56)	151 (55)
Surgery	32 (12)	25 (9)
Radiotherapy	26 (10)	40 (15)
Cytotoxic chemotherapy	113 (42)	105 (39)
Hormonal	1 (<1)	0 (0)
Anti-VEGF (other than bevacizumab)	29 (11)	27 (10)
Bevacizumab	52 (19)	54 (20)
Other antiangiogenic	24 (9)	25 (9)
Other	19 (7)	21 (8)

ITT, intention-to-treat; PD, progressive disease; VEGF, vascular endothelial growth factor.

Supplementary Table 2. Patients with TEAEs (safety population)

	Cilengitide arm (n=263) n (%)	Control arm (n=258) n (%)
TEAEs		
Any	261 (99)	253 (98)
Study treatment related	229 (87)	222 (86)
Considered as cilengitide related	132 (50)	NA
Serious AEs*		
Any	138 (53)	115 (45)
Study treatment related	55 (21)	47 (18)
Considered as cilengitide related	30 (11)	NA
NCI-CTCAE grade 3 or 4 TEAEs		
Any	169 (64)	158 (61)
Study treatment related	100 (38)	101 (39)
Considered as cilengitide related	52 (20)	NA
TEAEs leading to death		
Any	11 (4)	9 (4)
Study treatment related	3 (1)	3 (1)
Considered as cilengitide related	2 (1)	NA
TEAEs leading to permanent discontinuation of		
At least 1 study treatment	60 (23)	37 (14)
Cilengitide	43 (16)	NA
TEAEs leading to dose reduction of		
At least 1 study treatment	27 (10)	19 (7)
Cilengitide	12 (5)	NA

* A serious AE, experience, or reaction is any untoward medical occurrence that at any dose results in death or is life-threatening (ie, refers to an event in which the patient was at risk of death at the time of the event).

Study treatment-related: cilengitide, radiotherapy, and/or temozolomide.

AE, adverse event; NA, not applicable; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for AEs; TEAE, treatment-emergent AE.

Supplementary Table 3. Study treatment-related AEs leading to death by SOC/preferred term (safety population)*

	Cilengitide arm (n=263) n (%)	Control arm (n=258) n (%)
Number of patients with ≥ 1 AE	3 (1)	3 (1)
Blood and lymphatic system disorders	0	1 (<1)
Leukopaenia	0	1 (<1)
Lymphopaenia	0	1 (<1)
Neutropaenia	0	1 (<1)
Thrombocytopaenia	0	1 (<1)
Infections and infestations	0	3 (1)
Pneumonia	0	2 (1)
Septic shock	0	1 (<1)
Respiratory, thoracic, and mediastinal disorders	3 (1)	0
Pneumonia aspiration	1 (<1)	0
Pulmonary embolism	2 (1)	0

*If a patient experienced ≥ 1 AE within a SOC/preferred term, the patient was counted once in that SOC/preferred term.

Study treatment-related: cilengitide, radiotherapy, or temozolomide.

AE, adverse event; SOC, System Organ Class.

Appendix – list of participating institutions

Argentina: Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia - FLENI (B. Diez), Instituto Médico CER (M.S. Varela), Sanatorio Parque (S. Kahl)

Australia: Haematology & Oncology Clinics of Australia – HOCA (P. Eliadis), Royal Melbourne Hospital (M. Rosenthal), Austin Health (L. Cher), The Queen Elizabeth Hospital (K. Patterson), Royal North Shore Hospital (H. Wheeler), Calvary Mater Newcastle Hospital (S. Ackland), Royal Brisbane & Women's Hospital (J. Goh), Flinders Medical Centre (G. Kichenadasse)

Austria: Universitätsklinik für Innere Medizin I (C. Marosi), Universitätsklinik Graz (F. Payer), St. Johanns Spital – Landeskrankenhaus (R. Greil), Universitätsklinik Innsbruck (G. Stockhammer), Kaiser-Franz-Josef Spital (W. Grisold)

Belgium: UZ Brussel (B. Neyns), U.Z. Gasthuisberg (P. Clement), ZNA Middelheim (D. Schrijvers), Grand Hôpital Charleroi (J.L. Canon), Onze-Lieve-Vrouweziekenhuis (L. Verbeke), ZOL (J. Wuyts), UZ Gent (T. Boterberg), Cliniques universitaires UCL de Mont-Godinne (L. D'Hondt)

Brazil: Hospital Sao Lucas – PUCRS (F. Viola), HC da Faculdade de Medicina de Ribeirão Preto da USP (F. Maris Peria), IAMSPE (J.M. Rotta), Nucleo de Estudos Oncológicos (M.d. S. Oliveira), Hospital do Cancer - Instituto do Cancer do Ceara (M. Gifoni), CEPON (Y.V.N. Nascimento)

Canada: London Health Sciences Centre (D. MacDonald), Windsor Regional Cancer Centre (Y. Alam), Montreal Neurological Institute and Hospital McGill University (T. Muanza), Queen Elizabeth II Health Sciences Centre (M. MacNeil), Tom Baker Cancer Centre (G. Lim), CancerCare Manitoba (M. Pitz), Sunnybrook Health Sciences Centre (J. Perry), Cross Cancer Institute (D. Fulton), Hamilton Health Sciences- Juravinski Cancer Centre (H. Hirte), CHUS Hopital Fleurimont (D. Mathieu)

Czech Republic: Klinika Onkologie a Radioterapie - Fakultni nemocnice Hradec Kralove (J. Petera), Oddeleni radiacni onkologie - Krajska nemocnice Liberec (M. Machanova), Ustav radiacni onkologie 1LF UK - Fakultni nemocnice Na Bulovce (V. Stahalova), Radioterapeuticko-Onkologicke oddeleni Fakultni nemocnice v Motole (J. Prausova), Klinika radiacni onkologie - Masarykov onkologicky ustav (P. Slampa), Onkologicke a Radoterapeutické - oddeleni Fakultni nemocnice Plzen (J. Finek)

France: CH Pitié-Salpêtrière (J.Y. Delattre), CHU de la Timone (O. Chinot), Centre Val d'Aurelle Paul Lamarque (M. Fabbro), Centre René Gauducheau (M. Campone), Institut Gustave Roussy (J. Domont), CHU d'Angers (P. Menei), CLCC Paul Strauss (R. Schott), Hopital Neuro Cardiologique (J. Honnorat), CHRU Hopital Roger Salengro (F. Dubois), Institut Claudius Regaud (E. Moyal), Centre Antoine Lacassagne (M. Frenay), Hopital Pellegrin Tripode (H. Loiseau), Centre Léon Bérard (D. Frappaz), Hôpital Central - Service Neurologie (L. Taillandier), Centre Hospitalier de Valenciennes (E. Le Rhun), CHU Carémeau (C. Campello)

Germany: Universitaetsklinikum Dresden (D. Krex), Knappschafts Krankenhaus Bochum-Langendreer (U. Schlegel), LMU München - Klinikum Großhadern Neurochirurgische Klinik und Poliklinik (O. Schnell, J.C. Tonn), Universitaetsklinikum Freiburg (A. Weyerbrock), Charité - Universitaetsmedizin Berlin (P. Vajkoczy), Universitaetsklinikum Bonn (U. Herrlinger), Klinikum der J.W. Goethe Universitaet Frankfurt (J.P. Steinbach), Universitaetsklinikum Heidelberg (W. Wick), Universitaetsklinikum Regensburg (P. Hau), Universitaetsklinikum Ulm (T. Wiegel), Sozialstiftung Bamberg (P. Rieckmann), University Wuerzburg (G. Vince), Universitaetsklinikum Leipzig (R.D. Kortmann), Klinikum Nuernberg (J. Birkmann), Klinikum rechts der Isar TU Muechen (F. Schmidt), Universitaetsklinikum Magdeburg (G. Gademann), Universitaetsklinikum Schleswig-Holstein (H.M. Mehdorn), Universitaetsklinikum Goettingen (V. Rohde), Katharinenhospital (N.

Hopf), Universitaetsklinikum Hamburg-Eppendorf (O. Heese), Klinikum der Universität Köln (R. Goldbrunner). Vivantes-Klinikum Neukoelln (M. de Wit), Universitaetsklinikum Essen (W. Sauerwein)

Hong Kong: Queen Mary Hospital (J. Tsang), Tuen Mun Hospital (C.H. Wong)

Hungary: Debreceni Egyetem Orvos- és Egészségtudományi Centrum (J. Szanto), Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház (C. Olah), Szegedi Tudományegyetem (L. Thurzo), Kaposi Mór Oktató Kórház (K. Pali)

India: Ruby Hall Clinic Services Pvt. Ltd (A.B. Bhanage), Apollo Speciality Hospital (P. Mahadev), Indraprastha Apollo Hospital (G.K. Jadhav), Bangalore Institute of Oncology (N. Rao), ACTREC - Tata Memorial Center (T. Gupta)

Israel: Haddasah Ein Kerem M.C (T. Siegal), Rambam Health Care Campus (T. Tzuk), Chaim Sheba Medical Center (A. Taliansky), Tel-Aviv Sourasky Medical Center (D. Blumenthal), Rabin M.C (Y. Kundel)

Italy: Ospedale Bellaria (A. Brandes), IRCCS Istituto Nazionale Tumori "Regina Elena" (C. Carapella), Istituto Scientifico Ospedale San Raffaele (M. Reni), Fondazione IRCCS (A. Silvani), Ospedali Civili di Brescia (M. Scerrati), Istituto Clinico Humanitas (A. Santoro), Policlinico di Modena (P.F. Conte), Azienda Sanitaria Ospedaliera S. Giovanni Battista-Le Molinette (R. Soffietti), Ospedali Civili di Brescia (S.M. Magrini), Presidio Ospedaliero Marconi Bufalini (M. Faedi), Università degli studi-Policlinico Careggi (G. Biti), IRCCS Ospedale Busonera (V. Zagonel)

Netherlands: VU Medisch Centrum (J. Buter), Erasmus MC-Daniel den Hoed (M.J. vd Bent), Medisch Centrum Haaglanden (M.J.B. Taphoorn), St. Elizabeth Ziekenhuis (L.V. Beerepoot)

Poland: Centrum Onkologii (A. Kawecki), Centrum Onkologii - Instytut Oddział w Gliwicach (R. Tarnawski), Akademickie Centrum Kliniczne Szpital AM w Gdańsku (J. Jassem), Centrum Onkologii im. Prof. F. Łukaszczyka w Bydgoszczy (K. Roszkowski), ZOZ MSWiA (S. Nawrocki), Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Łodzi (J. Fijuth), Wielkopolskie Centrum Onkologii (K. Adamska), Beskidzkie Centrum Onkologii (D. Imielska-Zdunek), Dolnośląskie Centrum Onkologii (A. Maciejczyk), Specjalistyczny Szpital im. dr A. Sokolowskiego (I. Włodarska-Polinska), Centrum Onkologii Ziemi Lubelskiej (M. Mazurkiewicz)

Serbia: Clinical Hospital Center Zemun (I. Berisavac), Institute for Neurosurgery - Clinical Center Serbia (D. Grujicic)

Singapore: National Neuroscience Institute (E. Wang), National University Hospital (N. Chou)

Slovakia: Onkologický ústav svätej Alžbety (S. Spanik), Fakultná NsP Bratislava - Nemocnica akad. L. Derera (P. Kalina), Vychodoslovenský onkologický ústav a.s (P. Dubinsky), Fakultná nemocnica s poliklinikou F. Roosevelta (V. Malec), Národný onkologický ústav (I. Koza)

South Korea: Asan Medical Center (J.H. Kim), Catholic University of Korea - Seoul St. Mary's Hospital (Y.K. Hong), Korea Cancer Center Hospital (C.H. Rhee), Seoul National University Bundang Hospital (C.Y. Kim), Severance Hospital - Yonsei University College of Medicine (J.H. Chang Hun), Samsung Medical Center (D.H. Nam)

Spain: Hospital Clinic i Provincial (N. Vinolas), Hospital Universitario La Fe (G. Reynes), Hospital Vall d'Hebron (J. Rodon), Hospital Universitario La Paz (C. Belda), Hospital General de Valencia (A. Berrocal), Hospital Germans Trias i Pujol (C. Balaña), Hospital Clínico San Carlos Servicio de Oncología Planta Baja (P. Perez Segura), ICO-Institut Català d'Oncologia (S. del Barco), HGU de Elche (B. Sánchez)

Switzerland: Centre Hospitalier Universitaire Vaudois (R. Stupp), Inselspital - Universitätsspital Bern (A. Ochsenbein), Universitätsspital Zürich (M. Weller), Ospedale San Giovanni (G. Pesce), Kantonsspital Aarau (C. Mamot), Universitätsspital Basel (K. Conen), Kantonsspital St. Gallen (T. Hundsberger)

Taiwan: National Taiwan University Hospital (Y.K. Tu), Chi Mei Medical Center (C.C. Chio), Taichung Veterans General Hospital (C.C. Shen), Taipei Municipal WanFang Hospital (K.S. Hung), Chang-Gung Memorial Hospital - Linko (C.N. Chang)

United Kingdom: Clatterbridge Centre for Oncology (B. Haylock), Beatson West of Scotland Cancer Centre (A. James), Edinburgh Cancer Centre (S.C. Erridge), The Christie NHS FT (C. McBain), University College Hospital London (P. Mulholland), Aberdeen Royal Infirmary (D. Hurman)

USA: Duke University Medical Center (A. Desjardins), H. Lee Moffitt Cancer Center and Research Institute (E. Pan), Dartmouth-Hitchcock Medical Center (C. Fadul), University of Florida (E. Dunbar), Barrow Neurological Institute (L. Ashby), Baylor University Medical Center (K. Fink), The University of Tennessee (L.M. Michael), UC Davis Medical Center (R. Schrot), University of Washington School of Medicine (M. Mrugala), Henry Ford Health Systems (T. Mikkelsen), Washington University School of Medicine (K. Rich), Cedars-Sinai Medical Center (J. Rudnick), University of Rochester (N. Mohile), Case Medical Center (C. Nock), Columbia University Medical Center (R. Lai), Monmouth Medical Center (S. Raval), Wake Forest University Health Sciences (G. Lesser), Indiana University School of Medicine (E. Dropcho), Penn State Milton S. Hershey Medical Center (M. Glantz), Legacy Clinical Research & Technology Center (J. Chen), St. Francis Medical Group Indianapolis (G. Smith), North Shore University Hospital (M. Schulder), St. Lukes Hospital (M. Salacz), Virginia Piper Cancer Institute (J. Trusheim), University of Alabama at Birmingham (L. Nabors), Emory University (A. Voloschin), The Ohio State University (H. Newton), Vanderbilt University Medical Center (P. Moots), Tisch Hospital Center - New York University School of Medicine (D. Gruber), Langone Medical Center (H. Krouwer), University of Nebraska Medical Center (P. Bierman), LAC-USC Medical Center (T. Chen), Mount Sinai School of Medicine (A. Demopoulos), Rhode Island Hospital (S. Jeyapalan), Tupelo Neurology Clinic (R. Maron)